MedTrace Logo

Double-Blind Randomized Cross-Over Trial Comparing Metabolic Effects of Candesartan, Hydrochlorothiazide and Placebo

NCT00282178 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2008-10-16

No results posted yet for this study

Summary

The purpose of this study is to investigate the effect of a 12-week candesartan treatment compared with hydrochlorothiazide on insulin sensitivity assessed with hyperinsulinemic euglycemic clamp.

Conditions

Interventions

DRUG

Hydrochlorothiazide

25-50 mg once daily

DRUG

Placebo

Once daily

DRUG

Candesartan

16-32 mg once daily 12 weeks

Sponsors & Collaborators

  • Sahlgrenska University Hospital

    collaborator OTHER

  • AstraZeneca

    collaborator INDUSTRY

  • Umeå University

    lead OTHER

Principal Investigators

  • Jan Eriksson, MD, PhD · Dept of Medicine, Umeå University Hospital, Sweden

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-04-30
Primary Completion
2006-03-31
Completion
2006-04-30

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00282178 on ClinicalTrials.gov